11,418 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by Glazer Capital LLC

Glazer Capital LLC purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,418 shares of the company’s stock, valued at approximately $692,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Swedbank AB acquired a new stake in shares of Catalent during the 1st quarter worth about $1,659,000. DekaBank Deutsche Girozentrale grew its position in shares of Catalent by 2.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock valued at $1,763,000 after purchasing an additional 732 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the period. DNB Asset Management AS lifted its holdings in Catalent by 10.4% during the 2nd quarter. DNB Asset Management AS now owns 30,598 shares of the company’s stock worth $1,721,000 after purchasing an additional 2,887 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent during the 2nd quarter worth approximately $42,000.

Catalent Price Performance

CTLT stock opened at $61.11 on Friday. The company’s 50-day moving average price is $59.90 and its two-hundred day moving average price is $58.49. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm has a market cap of $11.09 billion, a P/E ratio of -27.04, a P/E/G ratio of 2.42 and a beta of 1.16.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on CTLT. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $63.40.

Insider Transactions at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,114 shares of company stock valued at $305,931. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.